Domestic market withdrawal of Forxiga remains a mystery
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.12.13 05:50:55
가나다라
0
Industry "Unusual case…withdrawal of an original drug that grosses KRW 50 bil a year in from the domestic market"
In contrast with Januvia, for which the marketing rights were sold to a domestic company before patent expiry
AZ’s official stance, "portfolio overhaul"... industry interest in AZ’s future activities
▲Pic of Forxiga
AstraZeneca’s decision to withdraw its SGLT-2 inhibitor diabetes drug Forxiga (dapagliflozin) from the Korean market is being considered an unusual move by the industry.This is because the decision to pull out of the Korean market would essentially mean giving up KRW 50 billion in annual sales for AstraZeneca.
While AstraZeneca's official position is that the decision is part of the company’s "portfolio overhaul," the mysteries surrounding the decision are not expected to be resolved anytime soon.
Therefore, the industry's eyes are on AstraZeneca's next move, especially as it has been in stark contrast with MSD’s treatment of Januvia (sitagliptin). MSD Korea, which had
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)